Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (Nasdaq: GH) is a precision oncology company that regularly issues news about its blood and tissue tests, real-world data initiatives, and AI analytics in cancer care. This news page aggregates company announcements, press releases, and other updates so readers can follow how Guardant’s technologies are being used in screening, monitoring, and treatment selection for cancer.
Recent Guardant Health news has covered topics such as preliminary financial results and test volumes, payer coverage milestones for the Shield blood test for colorectal cancer screening, and collaborations aimed at expanding access to oncology clinical trials. The company also reports on scientific presentations that highlight the performance of Guardant Reveal for minimal residual disease detection and therapy response monitoring, and Guardant360 Liquid for multiomic profiling and breast cancer subtyping.
Guardant’s updates frequently describe how its tests are applied across all stages of care, including early detection, recurrence monitoring, and advanced cancer management. News items also include information about partnerships with hospitals and research centers, participation in healthcare and investor conferences, and initiatives related to data infrastructure and AI-ready environments for large-scale genomic datasets.
Investors, clinicians, researchers, and others interested in Guardant Health can use this page to review the company’s latest press releases and historical announcements. By browsing this feed, readers can see how Guardant’s portfolio of liquid biopsy and precision oncology diagnostics is being deployed in clinical practice, research collaborations, and broader efforts to improve access to cancer screening and personalized treatment.
Guardant Health announced EU IVDR certification for its Guardant360 CDx liquid biopsy, allowing comprehensive genomic profiling across all solid cancers.
Certification by TÜV SÜD provides a significant milestone, ensuring compliance with stricter EU regulatory standards. This enables broader adoption and faster access to genomic profiling, aiding personalized treatment for advanced cancer patients.
Guardant360 CDx identifies somatic mutations using a blood sample, facilitating targeted therapies for non-small cell lung and breast cancer.
Clinical studies suggest that targeted therapies result in improved progression-free survival and higher response rates.
Adoption of genomic profiling with IVDR-certified liquid biopsy can address challenges like insufficient tissue for molecular profiling, ultimately benefiting more cancer patients.
Since its introduction, Guardant360 has been widely accepted, with over 500,000 tests performed and more than 400 peer-reviewed publications.
Guardant Health (Nasdaq: GH) announced on April 22, 2024, that its Compensation Committee has approved the granting of restricted stock units (RSUs) and non-qualified stock options to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. This move, compliant with Nasdaq Listing Rule 5635(c)(4), involves RSUs representing 215,601 shares of common stock to 94 employees and stock options to purchase 98,076 shares to three employees. The RSUs and stock options have a vesting schedule tied to continued employment, with stock options priced at $24.00 per share, the closing price on May 13, 2024.
Guardant Health (Nasdaq: GH) will present real-world data supporting the performance of its Shield™ blood test for colorectal cancer (CRC) screening at the 2024 Digestive Disease Week (DDW) in Washington, DC. The Shield test aims to increase CRC screening rates by offering a more convenient and less unpleasant method compared to traditional options. Presentations will include data showing improved screening rates and early detection of CRC. Initial results from the ECLIPSE study, validating Shield’s performance, were unveiled at the 2023 DDW, leading to a premarket approval (PMA) application to the FDA. An FDA Advisory Panel is set to review this application on May 23, 2024.
Guardant Health reported a 31% increase in revenue for the first quarter of 2024 compared to the same period in 2023. The company achieved significant revenue growth in precision oncology, driven by increased testing volume and reimbursement rates. Despite a decrease in free cash flow, Guardant Health raised its 2024 revenue guidance to $675-$685 million, showcasing a positive outlook for the year. The company also highlighted key milestones achieved in clinical data validation, product launches, and publication impact.
Guardant Health, Inc. (Nasdaq: GH) will participate in upcoming investor conferences including the BofA Securities 2024 Healthcare Conference and Leerink Partners 2024 Healthcare Crossroads Conference. Interested parties can access live and archived webcasts of the sessions on the company website.
Guardant Health, Inc. (Nasdaq: GH) has achieved a significant milestone by surpassing 500 peer-reviewed publications featuring its technology in esteemed scientific journals. These publications have had a profound impact on the oncology field, validating Companion Diagnostic claims and driving changes in NCCN guidelines. The company's accelerated publication rate of approximately 100 publications annually highlights its leadership in liquid biopsy research.
Summary not available.
Summary not available.
Summary not available.
Summary not available.